| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | ALX148 and KEYTRUDA (pembrolizumab) - (ASPEN-03) | Head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Merck & Company Inc. | Sotatercept - (SPECTRA) | Pulmonary arterial hypertension (PAH) | Phase 2 | Data Released | Subcutaneous | Cardiology |
| Merck & Company Inc. | Ensifentrine (RPL554) - Metered Dose Inhaler | Chronic obstructive pulmonary disease (COPD) | Phase 2 | Trial Completed | Inhalation | Respiratory |
| Merck & Company Inc. | MK-8591 | HIV | Phase 2 | oral | Anti-HIV | |
| Merck & Company Inc. | Ensifentrine (RPL554) DPI formulation | Maintenance treatment of COPD | Phase 2 | Trial Discontinued | Inhalation | Respiratory |
| Merck & Company Inc. | Rezafungin (CD101) - (STRIVE B) | Candidemia | Phase 2 | Trial Completed | Intravenous | Anti-Fungal |
| Merck & Company Inc. | Dalantercept - (DART) | Renal Cell Carcinoma (RCC) - cancer | Phase 2 | Intravenous | Oncology | |
| Merck & Company Inc. | ACE-083 | Facioscapulohumeral muscular dystrophy | Phase 2 | Intramuscular | Genetic Disorder |